Top

Published in:

01-09-2017 | Original Article

The effect of melatonin on gene expression of calcitonin gene-related peptide and some proinflammatory mediators in patients with pure menstrual migraine

Authors: Mohammad Ansari, Azam Karkhaneh, Asma Kheirollahi, Solaleh Emamgholipour, Mohammad Hessam Rafiee

Published in: Acta Neurologica Belgica | Issue 3/2017

Abstract

The neuropeptide calcitonin gene-related peptide (CGRP), a potent vasoactive and a marker of trigeminal inflammation, has been considered as an important mediator in various types of migraine such as pure menstrual migraine. Earlier studies have shown that CGRP can modulate the synthesis and release of other inflammatory factor including nitric oxide (NO) and interleukin-1beta (IL-1β) from trigeminal ganglion glial cells. Exogenous melatonin protects the tissues from inflammatory damages. The goal of this study was to determine the anti-inflammatory effects of melatonin on the CGRP expression, inducible nitric oxide synthase (iNOS) activity, NO, and IL-1β release in cultured peripheral blood mononuclear cells (PBMCs) from pure menstrual migraine patients and healthy subjects. This study was performed on 12 pure menstrual migraine patients and 12 age-and sex-matched healthy subjects. PBMCs were isolated and treated with melatonin for 12 h at pharmacological dose. Gene expression was evaluated by real-time PCR. CGRP and IL-1β proteins in culture supernatant were determined by ELISA method. iNOS activity in PBMCs was determined by colorimetric assays. Total nitrite as an indicator of NO concentrations in the culture supernatants was measured using Griess method. We found that melatonin treatment significantly decreases mRNA expression of CGRP release, NO production, and iNOS activity in the patient groups. Taken together, it appears that melatonin reduces inflammation through decreasing CGRP level and iNOS activity in the patients with migraine; however, further studies are needed in this regard.

Headache Classification Subcommittee of the International Headache S (2004) The international classification of headache disorders. Cephalalgia: Int J Headache 24:9CrossRef

Ruiz de Velasco I, Gonzalez N, Etxeberria Y, Garcia-Monco JC (2003) Quality of life in migraine patients: a qualitative study. Cephalalgia 23(9):892–900PubMedCrossRef

Silberstein SD, Merriam GR (1993) Sex hormones and headache. J Pain Symptom Manag 8(2):98–114CrossRef

MacGregor EA, Hackshaw A (2004) Prevalence of migraine on each day of the natural menstrual cycle. Neurology 63(2):351–353PubMedCrossRef

MacGregor EA, Frith A, Ellis J, Aspinall L, Hackshaw A (2006) Incidence of migraine relative to menstrual cycle phases of rising and falling estrogen. Neurology 67(12):2154–2158PubMedCrossRef

Goadsby PJ, Lipton RB, Ferrari MD (2002) Migraine-current understanding and treatment. N Engl J Med 346(4):257–270PubMedCrossRef

Edvinsson L (2003) New therapeutic target in primary headaches blocking the CGRP receptor. Expert Opin Ther Targets 7(3):377–383PubMedCrossRef

Goadsby PJ, Edvinsson L, Ekman R (1988) Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann Neurol 23(2):193–196PubMedCrossRef

Wimalawansa SJ (1996) Calcitonin gene-related peptide and its receptors: molecular genetics, physiology, pathophysiology, and therapeutic potentials. Endocr Rev 17(5):533–585PubMedCrossRef

10.

Zhang Z, Winborn CS, de Prado BM, Russo AF (2007) Sensitization of calcitonin gene-related peptide receptors by receptor activity-modifying protein-1 in the trigeminal ganglion. J Neurosci 27(10):2693–2703PubMedCrossRef

11.

Li J, Vause CV, Durham PL (2008) Calcitonin gene-related peptide stimulation of nitric oxide synthesis and release from trigeminal ganglion glial cells. Brain Res 1196:22–32PubMedPubMedCentralCrossRef

12.

Rothwell NJ, Hopkins SJ (1995) Cytokines and the nervous system II: actions and mechanisms of action. Trends Neurosci 18(3):130–136PubMedCrossRef

13.

Peres MFP, Masruha MR, Zukerman E, Moreira-Filho CA, Cavalheiro EA (2006) Potential therapeutic use of melatonin in migraine and other headache disorders. Expert Opin Investig Drugs 15(4):367–375PubMedCrossRef

14.

Esposito E, Cuzzocrea S (2010) Antiinflammatory activity of melatonin in central nervous system. Curr Neuropharmacol 8(3):228–242PubMedPubMedCentralCrossRef

15.

Brun J, Claustrat B, Saddier P, Chazot G (1995) Nocturnal melatonin excretion is decreased in patients with migraine without aura attacks associated with menses. Cephalalgia 15(2):136–139PubMedCrossRef

16.

Ebadi M, Govitrapong P, Phansuwan-Pujitu P, Nelson F, Reiter RJ (1998) Pineal opioid receptors and analgesic action of melatonin. J Pineal Res 24(4):193–200PubMedCrossRef

17.

Gilad E, Wong HR, Zingarelli B, Virág L, O’Connor M, Salzman AL, Szab C (1998) Melatonin inhibits expression of the inducible isoform of nitric oxide synthase in murine macrophages: role of inhibition of NF-κB activation. FASEB J 12(9):685–693PubMed

18.

Vijayalaxmi Reiter RJ, Tan D-X, Herman TS, Thomas CR (2004) Melatonin as a radioprotective agent: a review. Int J Radiat Oncol Biol Phys 59(3):639–653PubMedCrossRef

19.

Gavin DP, Sharma RP (2009) Chromatin from peripheral blood mononuclear cells as biomarkers for epigenetic abnormalities in schizophrenia. Cardiovasc Psychiatry Neurol 2009:409562PubMedPubMedCentralCrossRef

20.

Arosio B, D’Addario C, Gussago C, Casati M, Tedone E, Ferri E, Nicolini P, Rossi PD, Maccarrone M, Mari D (2014) Peripheral blood mononuclear cells as a laboratory to study dementia in the elderly. BioMed Res Int 2014:169203PubMedPubMedCentralCrossRef

21.

Acharyya S, Villalta SA, Bakkar N, Bupha-Intr T, Janssen PML, Carathers M, Li Z-W, Beg AA, Ghosh S, Sahenk Z (2007) Interplay of IKK/NF-κB signaling in macrophages and myofibers promotes muscle degeneration in Duchenne muscular dystrophy. J Clin Investig 117(4):889–901PubMedPubMedCentralCrossRef

22.

Avitsur R, Pollak Y, Yirmiya R (1997) Administration of lnterleukin-1 into the hypothalamic paraventricular nucleus induces febrile and behavioral effects. Neuroimmunomodulation 4(5–6):258–265PubMedCrossRef

23.

Ansar MM, Ansari M (2006) Nitric oxide involvement in pancreatic beta cell apoptosis by glibenclamide. Nitric Oxide: Biol Chem/Off J Nitric Oxide Soc 14(1):39–44. doi:10.1016/j.niox.2005.09.002 CrossRef

24.

Gupta S, Mehrotra S, Villalón CM, Perusquía M, Saxena PR, MaassenVanDenBrink A (2007) Potential role of female sex hormones in the pathophysiology of migraine. Pharmacol Ther 113(2):321–340PubMedCrossRef

25.

Couturier EGM, Bomhof MAM, Neven AK, Van Duijn NP (2003) Menstrual migraine in a representative Dutch population sample: prevalence, disability and treatment. Cephalalgia 23(4):302–308PubMedCrossRef

26.

Waeber C, Moskowitz MA (2005) Migraine as an inflammatory disorder. Neurology 64(10 suppl 2):S9–S15PubMedCrossRef

27.

Rodríguez-Osorio X, Sobrino T, Brea D, Martínez F, Castillo J, Leira R (2012) Endothelial progenitor cells a new key for endothelial dysfunction in migraine. Neurology 79(5):474–479PubMedCrossRef

28.

Aggarwal M, Puri V, Puri S (2012) Effects of estrogen on the serotonergic system and calcitonin gene-related peptide in trigeminal ganglia of rats. Ann Neurosci 19(4):151PubMedPubMedCentralCrossRef

29.

Durham PL (2004) CGRP-receptor antagonists–a fresh approach to migraine therapy? N Engl J Med 350(11):1073–1075PubMedCrossRef

30.

Ramadan NM (2005) Targeting therapy for migraine what to treat? Neurology 64(10 suppl 2):S4–S8PubMedCrossRef

31.

Regrigny O, Delagrange P, Scalbert E, Atkinson J, Lartaud-Idjouadiene I (1998) Melatonin improves cerebral circulation security margin in rats. Am J Physiol-Heart Circ Physiol 275(1):H139–H144

32.

Viswanathan M (2001) Melatonin inhibits calcitonin gene-related peptide-induced vasodilation and increase in cAMP in rat middle cerebral arteries. Eur J Pharmacol 415(2):247–250PubMedCrossRef

33.

Savaskan E, Olivieri G, Brydon L, Jockersb R, Kräuch K, Wirz-Justice A, Müller-Spahn F (2001) Cerebrovascular melatonin MT1-receptor alterations in patients with Alzheimer’s disease. Neurosci Lett 308(1):9–12PubMedCrossRef

34.

Guglielmo R, Martinotti G, Di Giannantonio M, Janiri L (2013) A possible new option for migraine management: agomelatine. Clin Neuropharmacol 36(2):65–67PubMedCrossRef

35.

Vogler B, Rapoport AM, Tepper SJ, Sheftell F, Bigal ME (2006) Role of melatonin in the pathophysiology of migraine. CNS Drugs 20(5):343–350PubMedCrossRef

36.

Murialdo G, Fonzi S, Costelli P, Solinas GP, Parodi C, Marabini S, Fanciullacci M, Polleri A (1994) Urinary melatonin excretion throughout the ovarian cycle in menstrually related migraine. Cephalalgia 14(3):205–209PubMedCrossRef

37.

Durham PL (2004) CGRP-receptor antagonists- a fresh approach to migraine therapy? N Engl J Med 350(11):1073–1075PubMedCrossRef

38.

Kankuri E, Asmawi MZ, Korpela R, Vapaatalo H, Moilanen E (1999) Induction of iNOS in a rat model of acute colitis. Inflammation 23(2):141–152PubMedCrossRef

39.

Clark AK, Old EA, Malcangio M (2013) Neuropathic pain and cytokines: current perspectives. J Pain Res 6:803–814PubMedPubMedCentral

40.

Lopez A, Garcia JA, Escames G, Venegas C, Ortiz F, Lopez LC, Acuña-Castroviejo D (2009) Melatonin protects the mitochondria from oxidative damage reducing oxygen consumption, membrane potential, and superoxide anion production. J Pineal Res 46(2):188–198PubMedCrossRef

41.

Crespo E, MaclAs M, Pozo D, Escames G, MartlN M, Vives F, Guerrero JM, AcunA-Castroviejo D (1999) Melatonin inhibits expression of the inducible NO synthase II in liver and lung and prevents endotoxemia in lipopolysaccharide-induced multiple organ dysfunction syndrome in rats. FASEB J 13(12):1537–1546PubMed

42.

Escames G, Lopez LC, Tapias V, Utrilla P, Reiter RJ, Hitos AB, Leon J, Rodríguez Maria I, Acuña-Castroviejo D (2006) Melatonin counteracts inducible mitochondrial nitric oxide synthase-dependent mitochondrial dysfunction in skeletal muscle of septic mice. J Pineal Res 40(1):71–78PubMedCrossRef

43.

Strecker T, Dux M, Messlinger K (2002) Increase in meningeal blood flow by nitric oxide interaction with calcitonin gene-related peptide receptor and prostaglandin synthesis inhibition. Cephalalgia 22(3):233–241PubMedCrossRef

44.

Chen H-M, Chen J-C, Ng C-J, Chiu D-F, Chen M-F (2006) Melatonin reduces pancreatic prostaglandins production and protects against caerulein-induced pancreatitis in rats. J Pineal Res 40(1):34–39PubMedCrossRef

45.

Bubenik GA, Blask DE, Brown GM, Maestroni GJM, Pang SF, Reiter RJ, Viswanathan M, Zisapel N (1998) Prospects of the clinical utilization of melatonin. Neurosignals 7(4):195–219CrossRef

46.

Jung KH, Hong S-W, Zheng H-M, Lee D-H, Hong S-S (2009) Melatonin downregulates nuclear erythroid 2-related factor 2 and nuclear factor-kappaB during prevention of oxidative liver injury in a dimethylnitrosamine model. J Pineal Res 47(2):173–183PubMedCrossRef

47.

Sulli A, Maestroni GJM, Villaggio B, Hertens E, Craviotto C, Pizzorni C, Briata M, Seriolo B, Cutolo M (2002) Melatonin serum levels in rheumatoid arthritis. Ann N Y Acad Sci 966(1):276–283PubMedCrossRef

48.

Peres MFP (2005) Melatonin, the pineal gland and their implications for headache disorders. Cephalalgia 25(6):403–411PubMedCrossRef

49.

Miano S, Parisi P, Pelliccia A, Luchetti A, Paolino MC, Villa MP (2008) Melatonin to prevent migraine or tension-type headache in children. Neurol Sci 29(4):285–287PubMedCrossRef

50.

Gimeno MF, Landa A, Sterin-Speziale N, Cardinali DP, Gimeno AL (1980) Melatonin blocks in vitro generation of prostaglandin by the uterus and hypothalamus. Eur J Pharmacol 62(4):309–317PubMedCrossRef

51.

Danilov A, Kurganova J (2016) Melatonin in Chronic Pain Syndromes. Pain and therapy 5:1–17PubMedPubMedCentralCrossRef

Title: The effect of melatonin on gene expression of calcitonin gene-related peptide and some proinflammatory mediators in patients with pure menstrual migraine
Authors: Mohammad Ansari
Azam Karkhaneh
Asma Kheirollahi
Solaleh Emamgholipour
Mohammad Hessam Rafiee
Publication date: 01-09-2017
Publisher: Springer International Publishing
Published in: Acta Neurologica Belgica / Issue 3/2017
Print ISSN: 0300-9009
Electronic ISSN: 2240-2993
DOI: https://doi.org/10.1007/s13760-017-0803-x

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

The effect of melatonin on gene expression of calcitonin gene-related peptide and some proinflammatory mediators in patients with pure menstrual migraine

Abstract

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2017

Primary central nervous system lymphoma of T-cell origin: an unusual cause of spinal cord disease

Alzheimer’s disease CSF biomarkers: clinical indications and rational use

Syndrome of the trephined revealed by vertical diplopia

Subacute onset Hirayama disease with extensive myelopathy on MRI in flexed posture

Neuron-specific enolase levels as a marker for possible neuronal damage in idiopathic intracranial hypertension

Microcystic meningioma: difficulties in diagnosis and magnetic resonance imaging findings